表紙:全身性エリテマトーデスの世界市場-2023-2030
市場調査レポート
商品コード
1279681

全身性エリテマトーデスの世界市場-2023-2030

Global Systemic Lupus Erythematosus Market - 2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=154.36円
全身性エリテマトーデスの世界市場-2023-2030
出版日: 2023年05月26日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

全身性エリテマトーデスの世界市場は、2022年に18億9,320万米ドルに達し、2030年には32億9,570万米ドルに達することで有利な成長が予測されます。全身性エリテマトーデス市場は、予測期間中(2023年~2030年)に7.3%のCAGRを示すと予測されます。

全身性エリテマトーデス(SLE)は、慢性的な自己免疫疾患であり、免疫システムが健康な組織を誤って攻撃することにより、皮膚、関節、腎臓、心臓、肺、脳などに害を及ぼすことがあります。SLEは女性に多く、通常25歳から45歳の間に発症します。

慢性的な炎症と様々な症状を引き起こし、人のQOLを低下させる可能性があります。全身性エリテマトーデスの世界市場は、本疾患に関する知識の増加、診断率の向上、新規治療法の発見により、今後数年間で大きく成長すると予測されています。

市場力学

政府別イニシアチブの増加が、世界の全身性エリテマトーデス市場の成長を促進すると予想されます

世界中の政府は、SLEの治療法や治療法へのアクセスを向上させ、研究開発への金銭的支援を増やし、患者さんの転帰を改善するための規制を推進することに取り組んでいます。

例えば、米国疾病管理予防センター(CDC)の2022年版レポートによると、CDC-RFA-DP20-2008は、5年間の協力協定を結んだ資金調達機会告知(NOFO)であり、閉鎖的なものです。この協力協定の基本的な目標は、狼瘡の認識と能力を向上させるための全国的な取り組みを行う国内組織を支援し、協力関係を構築することです。

本協定は、狼瘡の兆候を認識し、発見された場合に適切な対応ができるヘルスケア従事者を増加させることを目的としています。さらに、本協定は、狼瘡患者の自己管理ツールやサービスへの参加を増やし、その結果、患者の自己管理行動を良好に変化させることを意図しています。したがって、上記の要因により、予測期間中、世界の全身性エリテマトーデス市場の成長が促進されると予想されます。

全身性エリテマトーデスの世界市場は、治療の副作用別制約に直面する可能性があります

既存のSLE治療薬の多くは、重篤な副作用の可能性があり、患者の使用を妨げる可能性があります。患者はかなりの副作用がある治療法の採用に消極的であり、これが大きな市場制約となる可能性があります。

プレドニゾンは、炎症を抑え、関節痛や皮疹などの症状を緩和するのに役立つコルチコステロイドの一例ですが、体重増加、高血圧、骨粗鬆症などの深刻な副作用があることもあります。

COVID-19の影響分析

COVID-19の流行に伴い、全身性エリテマトーデス(SLE)が世界市場に大きな影響を及ぼしています。患者の医療へのアクセスが制限されることは、パンデミックの重大な影響の1つです。SLE患者の多くは免疫力が低下しており、重症のCOVID-19を発症しやすいため、医療機関を受診する人が少なくなり、特定や治療の遅れが生じます。

これは、患者の転帰に悪影響を及ぼす可能性があります。COVID-19の流行は、SLE治療薬の市場への流入を妨げ、その結果、不足が生じ、患者やヘルスケアシステムにとって価格が上昇することになりました。

ロシア・ウクライナ紛争分析

ロシアとウクライナの紛争は、全世界の全身性エリテマトーデス(SLE)市場、特にSLE治療薬のサプライチェーンに意図しない結果をもたらす可能性があります。ウクライナは重要な医薬品メーカーとなりつつあり、他国へ医薬品を輸出しています。戦争の結果、生産施設や輸送ルートが破壊されたり閉鎖されたりした場合、SLE治療薬のサプライチェーンに影響を与える可能性があります。

さらに、紛争の結果、地域のヘルスケアインフラやアクセス性が低下し、ウクライナおよび周辺地域の全身性エリテマトーデス(SLE)患者が診断や治療に長時間待たされることになる可能性があります。しかしながら、全身性エリテマトーデスの世界市場は多様であり、医薬品の供給が特定の地域や国に大きく依存しているわけではありません。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 薬物クラス別スニペット
  • デリバリーモード別スニペット
  • 販売チャネル別
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 政府のイニシアティブの高まりが、世界の全身性エリテマトーデス市場を牽引すると予想されます
    • 抑制要因
      • 全身性エリテマトーデスの世界市場は、治療別副作用による制約に直面する可能性があります
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 法規制の分析

第6章 COVID-19の分析

  • COVID-19の分析
    • COVID-19登場前シナリオ
    • 現在のCOVID-19シナリオ
    • COVID-19後または将来のシナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • サマリー

第7章 薬剤クラス別

  • 抗マラリア薬
  • 非ステロイド性抗炎症薬
  • 細胞毒性・免疫抑制剤
  • 生物学的製剤
  • その他

第8章 デリバリーモード別

  • 静脈内投与
  • 皮下投与
  • 経口
  • 局所投与

第9章 流通チャネル別

  • 小売薬局
  • 病院薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 競合シナリオ
  • 市況ポジショニング/シェア分析
  • M&A(合併・買収)分析

第12章 企業プロファイル

  • Anthera Pharmaceuticals Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展状況
  • Eli Lilly
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche Ltd
  • Pfizer Limited
  • Sanofi
  • Lycera Corporation
  • Bristol-Myers Squibb
  • ImmuPharma Plc
  • Merck KGaA

第13章 付録

目次
Product Code: PH51

Market Overview

The global systemic lupus erythematosus market reached US$ 1,893.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 3,295.7 million by 2030. The systemic lupus erythematosus market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030).

Systemic lupus erythematosus (SLE) is a chronic autoimmune condition that can harm the skin, joints, kidneys, heart, lungs, and brain by causing the immune system to wrongly target healthy tissues. SLE is more frequent in women and usually occurs between the ages of 25 and 45.

Chronic inflammation and a variety of symptoms can be caused by the condition, lowering a person's quality of life. The global market for systemic lupus erythematosus is predicted to rise significantly in the next years due to increasing knowledge of the disorder, higher rates of diagnosis, and the discovery of novel therapies.

Market Dynamics

The Rising Number of Government Initiatives is Expected to Drive the Global Systemic Lupus Erythematosus Market Growth.

Governments throughout the world are working to enhance access to SLE treatments and therapies, increase monetary support for R&D, and promote regulations that improve outcomes for patients.

For instance, according to the Centers for Disease Control and Prevention (CDC) 2022 report, the CDC-RFA-DP20-2008 is a closed Notice of Funding Opportunity (NOFO) with a 5-year collaboration agreement. The fundamental goal of this cooperation agreement is to support national organizations in undertaking national initiatives to improve lupus awareness and abilities, as well as to build collaborations.

The goal of this agreement is to increase the number of healthcare practitioners who can recognize lupus signs and take appropriate action if it is detected. Furthermore, the agreement intends to increase lupus patients' participation in self-management tools and services, resulting in a favorable shift in their self-management behaviors. Therefore, the above-mentioned factors, are expected to drive growth of the global systemic lupus erythematosus market over the forecast period.

The Global Systemic Lupus Erythematosus Market May Face Constraints Due to Adverse Effects of Treatment.

Many of the existing SLE therapies have potentially serious side effects, which may prevent patients from using them. Patients may be reluctant to adopt therapies that have considerable adverse effects, which can be a big market restriction.

Prednisone is an example of a corticosteroid that can help reduce inflammation and relieve symptoms like joint pain and skin rashes, but it can also have serious adverse effects including weight gain, high blood pressure, and osteoporosis.

COVID-19 Impact Analysis

In the wake of the COVID-19 epidemic, Systemic Lupus Erythematosus (SLE) has had a substantial influence on the global market. Restricted patient access to medical care has been one of the pandemic's significant effects. Delays in identification and treatment occur as a result of fewer individuals seeking medical attention due to the fact that many SLE patients have compromised immune systems and are more likely to develop severe COVID-19.

This can have a detrimental effect on patient outcomes. The COVID-19 pandemic has also hampered the flow of SLE medications into the market, resulting in shortages and raising prices for patients and healthcare systems.

Russia Ukraine Conflict Analysis

The crisis between Russia and Ukraine may have unintended consequences for the worldwide market for systemic lupus erythematosus (SLE), especially for the SLE drug supply chain. Ukraine is becoming a significant pharmaceutical manufacturer, exporting medicines to other nations. The supply chain for SLE drugs may be affected if production facilities or shipping routes are destroyed or shut down as a result of the war.

In addition, the conflict may result in a decline in the region's healthcare infrastructure and accessibility, which would cause SLE patients in Ukraine and the surrounding territories to wait longer for diagnosis and treatments. The worldwide market for SLE is diversified, nevertheless, and does not rely largely on any one area or nation for the provision of medicines.

Segment Analysis

The global systemic lupus erythematosus market is segmented based on drug class, mode of delivery, distribution channel, and region.

The Hospital Pharmacies Segment is Expected to Dominate the Global Systemic Lupus Erythematosus Market.

The systemic lupus erythematosus (SLE) medication distribution is anticipated to be dominated by hospital pharmacies on a worldwide scale accounting market share of 42.4%. Hospital pharmacies may supply patients with the essential drugs and other therapies and are the main point of care for SLE patients, especially those with severe or complex forms of the condition. Personalised drug dosage and monitoring, as well as access to specialised therapies like intravenous infusions or diagnostic testing, are advantages that hospital pharmacists offer.

Additionally, they already have contacts with healthcare professionals, which makes it simpler to prescribe and monitor drugs as well as to communicate and coordinate treatment. Therefore, owing to the above factors, the hospital pharmacies segment is likely to play major role in accelarating the global systemic lupus erythematosus market growth.

Geographical Analysis

North America Region Holds The Largest Market Share of the Global Systemic Lupus Erythematosus Market.

The global systemic lupus erythematosus market is dominated by North America and holds 1/3rd market share, due to a number of factors, first off, there is more knowledge regarding SLE in this area, which has improved knowledge of the condition and available treatments. Second, compared to other locations, North America has a more established healthcare system, which gives SLE sufferers greater access to medical care and specialised therapies.

In addition, there have been more foundations and independent venture firms funding North American biopharmaceutical producers, which has aided in the creation of novel SLE medications and treatments. For instance, in March 2023, AbbVie revealed the findings of a Phase II research in patients with moderately to highly active systemic lupus erythematosus (SLE) with upadacitinib (RINVOQ, 30 mg) administered alone or in combination treatment (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg) once daily.

Competitive Landscape

The major global players in the market include: Anthera Pharmaceuticals, Eli Lilly, GlaxoSmithKline, F. Hoffmann-La Roche, Pfizer Limited, Sanofi, Lycera Corporation, Bristol-Myers Squibb, ImmuPharma Plc, and Merck KGaA.

Why Purchase the Report?

  • To visualize the global systemic lupus erythematosus- market segmentation based on drug class, mode of delivery, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global systemic lupus erythematosus market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global systemic lupus erythematosus market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Mode of Delivery
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising number of government initiatives is expected to drive the global systemic lupus erythematosus market.
    • 4.1.2. Restraints
      • 4.1.2.1. The global systemic lupus erythematosus market may face constraints due to adverse effects of treatment.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 7.1.2. Market Attractiveness Index, By Drug Class
  • 7.2. Antimalarial Drugs
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Non-Steroidal Anti-Inflammatory Drugs
  • 7.4. Cytotoxic And Immunosuppressive Drugs
  • 7.5. Biologics
  • 7.6. Others

8. By Mode of Delivery

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 8.1.2. Market Attractiveness Index, By Mode of Delivery
  • 8.2. Intravenous
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Subcutaneous
  • 8.4. Oral
  • 8.5. Topical

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Retail Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Anthera Pharmaceuticals Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Eli Lilly
  • 12.3. GlaxoSmithKline Plc
  • 12.4. F. Hoffmann-La Roche Ltd
  • 12.5. Pfizer Limited
  • 12.6. Sanofi
  • 12.7. Lycera Corporation
  • 12.8. Bristol-Myers Squibb
  • 12.9. ImmuPharma Plc
  • 12.10. Merck KGaA

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us